Canada Life
CBIO

Canada Life’s Crescent Biopharma CBIO Stock Holding History

Canada Life’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-38
Closed -$45K – 1582
2019
Q2 		$45K Hold
38
– – ﹤0.01% 2468
2019
Q1 		$47K Hold
38
– – ﹤0.01% 2264
2018
Q4 		$35K Hold
38
– – ﹤0.01% 2469
2018
Q3 		$55K Hold
38
– – ﹤0.01% 2370
2018
Q2 		$62K Buy
+38
New +$65.3K ﹤0.01% 2353

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Canada Life's CBIO Position: Q3 2019 in Review

Canada Life sold out of Crescent Biopharma (CBIO) in Q3 2019, closing a stake of 38 shares — an estimated $45K sold.

Canada Life first reported a position in CBIO in Q2 2018 and held it in 5 quarters. The position peaked at $62K in Q2 2018. 75 funds tracked by Wall St. Rank hold CBIO as of Q3 2019.

  • Canada Life reported no remaining Crescent Biopharma position as of Q3 2019 after selling out during the quarter.
  • Canada Life sold 38 Crescent Biopharma shares in Q3 2019, an estimated $45K.
  • Canada Life first reported a position in Crescent Biopharma in Q2 2018 and held it in 5 quarters.
  • Canada Life's Crescent Biopharma position peaked at $62K in Q2 2018.
  • 75 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2019.

Based on Canada Life's 13F filing for Q3 2019, filed 25 Oct 2019.